[{"address1": "Modi\u2019in Technology Park", "address2": "2 HaMa\u2019ayan Street", "city": "Hevel Modi'in", "zip": "7177871", "country": "Israel", "phone": "972 8 642 9100", "fax": "972 8 642 9101", "website": "https://www.biolinerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.", "fullTimeEmployees": 79, "companyOfficers": [{"maxAge": 1, "name": "Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA", "age": 63, "title": "Chief Executive Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 598000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mali  Zeevi CPA, CPA", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 374000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ella  Sorani Ph.D.", "age": 55, "title": "Chief Development Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 452000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Holly W. May M.B.A.", "age": 61, "title": "President of BioLineRx USA", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 710000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Lacey", "title": "Head of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tsipi  Keren-Lehrer B.Sc., L.L.B.", "title": "Head of BD & Strategic Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Raziel  Fried", "title": "Treasurer & Budgetary Control Director", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.5299, "open": 0.52, "dayLow": 0.5107, "dayHigh": 0.5675, "regularMarketPreviousClose": 0.5299, "regularMarketOpen": 0.52, "regularMarketDayLow": 0.5107, "regularMarketDayHigh": 0.5675, "beta": 0.875, "forwardPE": -1.3014286, "volume": 360756, "regularMarketVolume": 360756, "averageVolume": 375809, "averageVolume10days": 296190, "averageDailyVolume10Day": 296190, "bid": 0.5167, "ask": 0.582, "bidSize": 100, "askSize": 100, "marketCap": 43694816, "fiftyTwoWeekLow": 0.51, "fiftyTwoWeekHigh": 2.53, "priceToSalesTrailing12Months": 3.749019, "fiftyDayAverage": 0.6432, "twoHundredDayAverage": 1.1833, "currency": "USD", "enterpriseValue": 577070656, "floatShares": 989893595, "sharesOutstanding": 79939296, "sharesShort": 212051, "sharesShortPriorMonth": 219066, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0027, "heldPercentInsiders": 0.08543, "heldPercentInstitutions": 0.01713, "shortRatio": 0.6, "impliedSharesOutstanding": 75170304, "bookValue": 0.012, "priceToBook": 45.55, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -49148000, "trailingEps": -0.76, "forwardEps": -0.42, "pegRatio": 0.05, "lastSplitFactor": "1:15", "lastSplitDate": 1563148800, "enterpriseToRevenue": 49.513, "enterpriseToEbitda": -15.389, "52WeekChange": -0.67261904, "SandP52WeekChange": 0.26253593, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BLRX", "underlyingSymbol": "BLRX", "shortName": "BioLineRx Ltd.", "longName": "BioLineRx Ltd.", "firstTradeDateEpochUtc": 1311773400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e62a36f1-05bb-3c53-9aee-d33adfbdf394", "messageBoardId": "finmb_5015080", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.5466, "targetHighPrice": 21.0, "targetLowPrice": 6.5, "targetMeanPrice": 13.75, "targetMedianPrice": 13.75, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 28173000, "totalCashPerShare": 0.026, "ebitda": -37500000, "totalDebt": 11314000, "quickRatio": 1.319, "currentRatio": 1.494, "totalRevenue": 11655000, "debtToEquity": 86.631, "revenuePerShare": 0.18, "returnOnAssets": -0.40497002, "returnOnEquity": -1.884, "freeCashflow": -17292376, "operatingCashflow": -28701000, "grossMargins": 0.55839, "operatingMargins": -0.70343, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-08"}]